Welcome to our dedicated page for Trendlines Group news (Ticker: TRNLY), a resource for investors and traders seeking the latest updates and insights on Trendlines Group stock.
Trendlines Group (TRNLY) is a strategic investment firm driving innovation in medical technology, agricultural biotech, and therapeutic development. This news hub provides investors and industry observers with essential updates on TRNLY's portfolio advancements, regulatory milestones, and market strategies.
Access real-time updates on clinical trial progress, licensing agreements, and strategic partnerships that shape the company's growth trajectory. Our curated news collection serves as a centralized resource for tracking TRNLY's role in commercializing breakthrough technologies across healthcare and sustainable agriculture sectors.
Key content categories include:
- Investment announcements in novel medical devices
- Biotechnology partnerships advancing therapeutic solutions
- Agricultural innovation developments addressing food security
- Regulatory updates impacting portfolio companies
Bookmark this page for continuous access to verified TRNLY updates, ensuring informed decision-making through comprehensive coverage of their value creation activities.
The Trendlines Group Ltd. has invested in AgriG8 Pte Ltd., marking its entry into the agri-fintech sector. AgriG8 aims to enhance access to financing for smallholder farmers, a critical segment in global agriculture. Utilizing big data and AI, the platform encourages farmers towards sustainable practices, altering borrowing rates based on behavior. The initiative plans to pilot its services in Q1 2022 and expand into Africa and Indonesia by Q3 2022. Trendlines acknowledges the significant gap in financing for small farmers and believes AgriG8's approach is innovative and beneficial.
FruitSpec has completed a $5 million investment round led by Amathaon Capital, Ocean Azul, and Smart Agro. The funding will enhance their Yield Management Platform, which improves fruit supply-chain management through accurate yield predictions and digital tools. This platform addresses operational inefficiencies and aims to increase profitability within the $5.4 billion US fresh produce market. CEO Raviv Kula emphasizes the global expansion efforts with this funding, highlighting growth opportunities in markets like Chile, the US, South Africa, and Spain.
Vensica Therapeutics, a clinical-stage biopharmaceutical company based in Israel, announced a successful investment round, closing $16 million. The round was led by Israel Biotech Fund and included notable investors such as Laborie and The Trendlines Group. The funds will support Vensica's phase II clinical trials in the US and Europe, focusing on its needle-free ultrasound-assisted drug delivery platform for treating urological conditions like overactive bladder. CEO Avner Geva expressed optimism for innovative treatment solutions in bladder diseases, while the company plans to expand its workforce in Israel.
Fidmi Medical Ltd., based in Israel, has successfully completed a $2.2 million financing round and launched its FDA-cleared low-profile Percutaneous Endoscopic Gastrostomy (PEG) device in the U.S. The financing round included notable investors such as Micro-Tech Co., Ltd. and The Trendlines Group. This innovative gastrostomy device, designed for long-term nutritional support, targets a market worth $800 million. Its replaceable inner tube and stable internal bumper aim to reduce complications and healthcare costs, enhancing patient quality of life.
Röchling Medical and Trendlines Innovation Labs announced a collaboration on Oct. 6, 2021, to enhance medical device innovation and manufacturing. The partnership aims to create a comprehensive solution for product development in the healthcare industry, leveraging Röchling's expertise in manufacturing and Trendlines' strengths in R&D. Röchling Medical has a proven track record in the life sciences, while Trendlines focuses on early-stage development of medical technologies. This collaboration seeks to improve health outcomes globally by addressing critical unmet needs.
CoreBone, based in Tel Aviv, Israel, has announced a successful investment round, raising $3.7 million. The investment includes $3 million from the Guangzhou Sino-Israel Biotech Investment Fund for its Chinese subsidiary, alongside $700,000 from The Trendlines Group and Agriline. This funding will facilitate the expansion of CoreBone's bioactive, coral-based bone graft materials into the rapidly growing Chinese market, which bans the import of foreign human-derived grafts, thus presenting a unique opportunity for CoreBone's products.
The Trendlines Group (OTCQX: TRNLY) will present at the Lytham Partners Fall 2021 Investor Conference on October 5, 2021, from 8:45-9:15 AM ET. A webcast of the presentation will be available live and archived on Trendlines' website.
Management will also hold virtual one-on-one meetings during the conference from October 5-7. Interested parties can contact Lytham Partners to arrange meetings.
MetoMotion, a developer of intelligent robotic systems for agriculture, has secured a $5 million investment led by Ridder and Navus Ventures. The funding will finalize R&D efforts, set up production, and launch commercial products aimed at addressing labor shortages in greenhouse farming. The GRoW robot utilizes AI for harvesting and improves crop management through data collection. This partnership enhances MetoMotion's capabilities and aims to revolutionize greenhouse operations by automating labor-intensive tasks, ultimately reducing production costs and improving yields.
AgroScout has successfully completed a $7.5 million Series A funding round to enhance its AI cloud platform for remote agronomy. This initiative aims to serve the 500 million largely unserved farms globally, enabling sustainable crop protection and carbon accountability. The investment was led by Kibbutz Yotvata, alongside other investors including Agriline and The Trendlines Group. AgroScout's platform offers actionable insights for crop management, decreases pesticide usage, and supports early pest detection to improve yields. The company focuses on affordable, efficient farming solutions for growers.
Vessi Medical has completed its first-in-human procedure using its cryoablation solution for non-muscle invasive bladder cancer (NMIBC) at Rambam Healthcare Campus, Israel. The procedure was successful, demonstrating ease of use and no complications, with the patient reporting no pain post-discharge. This marks a significant step towards regulatory approval for Vessi's minimally invasive treatment, which aims to improve patient quality of life compared to traditional surgical options.
